- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05259709
En studie av ImmunoPet Imaging ved bruk av 89Zr-DFO-REGN5054 hos voksne deltakere med solid kreft behandlet med Cemiplimab
En første-i-menneske-studie av 89Zr-DFO-REGN5054 (Anti-CD8) positronemisjonstomografi hos pasienter med solide maligniteter behandlet med Cemiplimab
This study is researching an experimental drug called 89Zr-DFO-REGN5054 and cemiplimab. The study is focused on patients with a type of cancer that can be potentially imaged using 89Zr-DFO-REGN5054 and show special tumor features that may be important to the way the immune system fights cancer.
The aim of the study is to study the safety and tolerability (how the body reacts to the drug) of the imaging agent 89Zr-DFO REGN5054.
The study is looking at several other research questions, including:
- What side effects may happen from taking the study drugs
- How much study drug is in the blood at different times
- Whether the body makes antibodies against the study drugs (which could make the study drugs less effective or could lead to side effects)
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
-
Groningen, Nederland, 9700 RB
- UMC Groningen
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Key Inclusion Criteria:
- Advanced or metastatic solid tumors that may respond to anti-programmed cell death 1 (PD-1) immunotherapy
- Measurable disease according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 criteria
- Eastern Cooperative Oncology Group (ECOG) performance status of ≤1
- Adequate organ and bone marrow function as defined in the protocol
- Willing and able to comply with clinic visits and study-related procedures (including required tumor biopsy for Part B)
Key Exclusion Criteria:
- Currently receiving another cancer treatment or inadequate time since last therapy, as defined in the protocol
- Has not yet recovered from acute toxicities from prior therapy; exceptions defined in the protocol
- Prior treatment with a blocker of the PD-1/Programmed death ligand 1 (PD-L1) pathway
- Currently receiving or has received chimeric antigen receptor (CAR-T) cell therapy
- Symptomatic or untreated brain metastases, leptomeningeal disease, or spinal cord compression
- Known history of or any evidence of interstitial lung disease, active, noninfectious pneumonitis (past 5 years) or active tuberculosis
NOTE: Other protocol defined inclusion/exclusion criteria apply.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Sekvensiell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Single ascending dose of 89Zr˗DFO˗REGN5054 followed by fixed dose of cemiplimab
Part A: Doses of 89Zr˗DFO˗REGN5054 may be reduced based upon assessment. |
Administered by intravenous (IV) infusion during Part A and B. Administered by IV infusion every 3 weeks (Q3W).
Andre navn:
|
|
Eksperimentell: Defined dose of 89Zr˗DFO˗REGN5054 followed by fixed dose of cemiplimab
Part B: Defined dose of 89Zr˗DFO˗REGN5054 determined in Part A. |
Administered by intravenous (IV) infusion during Part A and B. Administered by IV infusion every 3 weeks (Q3W).
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence and severity of treatment-emergent adverse events (TEAEs)
Tidsramme: Up to day 8, after the infusion of 89Zr˗DFO˗REGN5054
|
Part A |
Up to day 8, after the infusion of 89Zr˗DFO˗REGN5054
|
|
Incidence and severity of TEAEs
Tidsramme: Up to approximately week 115
|
Part A and B |
Up to approximately week 115
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Clinical dosimetry based on tissue radiation absorbed dose calculated from positron emission tomography (PET) image acquisition data
Tidsramme: On days 1, 5 and 8
|
After injection of 37 megabecquerel (MBq) of 89Zr-DFO-REGN5054, a series of whole-body positron emission tomography (PET) images will be obtained over a period of up to 8 days and corrected for attenuation by low-dose computed tomography (CT) scans using PET/CT. The radiation effective dose per organ/tissue will be calculated for each organ using Organ Level INternal Dose Assessment/EXponential Modeling (OLINDA/EXM). The unit of effective dose per organ/tissue will be millisievert per Minimum Base Quantity (MBq) for each participant's organ/tissue. The final values for each organ will be averaged across participants for each mass dose |
On days 1, 5 and 8
|
|
Clinical dosimetry based on tissue radiation effective dose calculated from PET image acquisition data
Tidsramme: On days 1, 5 and 8
|
After injection of 37 MBq of 89Zr-DFO-REGN5054, a series of whole-body PET images will be obtained over a period of up to 8 days and corrected for attenuation by low-dose CT scans using PET/CT. The radiation effective dose for the whole body will be calculated using OLINDA/EXM software. The unit of effective dose will be millisievert per MBq for the whole body for each participant. The final values will be averaged across participants for each mass dose. |
On days 1, 5 and 8
|
|
Concentration of 89Zr-DFO-REGN5054 in serum
Tidsramme: On days 1, 5 and 8
|
Part A |
On days 1, 5 and 8
|
|
Serum imaging agent activity concentration of area under the curve (AUC0-7)
Tidsramme: Up to day 8
|
Part A |
Up to day 8
|
|
89Zr-DFO-REGN5054 uptake across cluster of differentiation 8 (CD8)-expressing normal tissues and tumors
Tidsramme: At the time of imaging, up to day 8
|
Part A and Part B |
At the time of imaging, up to day 8
|
|
Blood pool uptake of 89Zr-DFO-REGN5054 with subsequent calculation of standardized uptake value (SUV) tumor-to-blood ratios
Tidsramme: At the time of imaging, up to day 8
|
Part A and Part B |
At the time of imaging, up to day 8
|
|
Association of 89Zr˗DFO˗REGN5054 autoradiographic signal intensity distribution with CD8 expression in tumor tissues
Tidsramme: At Baseline
|
Part A and Part B |
At Baseline
|
|
Association of 89Zr-DFO-REGN5054 uptake with CD8 expression in tumor tissues
Tidsramme: At Baseline
|
Part B |
At Baseline
|
|
Association of tumor-to-blood ratio of 89Zr-DFO-REGN5054 with CD8 expression in tumor tissues
Tidsramme: At Baseline
|
Part B |
At Baseline
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Clinical Trials Management, Regeneron Pharmaceuticals
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- R5054-ONC-1843
- 2019-001604-38 (EudraCT-nummer)
- 2019 (U.S. NIH-stipend/kontrakt)
- 2024-515351-37-00 (Ctis)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
IPD-delingstidsramme
When Regeneron has:
- received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
- made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
- the legal authority to share the data, and
- ensured the ability to protect participant privacy
Tilgangskriterier for IPD-deling
Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
- ICF
- ANALYTIC_CODE
- CSR
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .